I

    Immunitybio Inc (IBRX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $8.05
    -0.35 (-4.17%)

    Market Cap: $8.43B

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    57%(23/40)
    Avg Surprise
    -2.40%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.05
    Range$-0.09 - $0.00
    3 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.06-20.0%
    60d ago$-0.07-40.0%
    30d ago$-0.07-40.0%
    7d ago$-0.07-40.0%
    Current$-0.05
    Revenue Consensus
    $59M
    Range$56M - $66M
    4 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.71
    Range$-0.73 - $-0.70
    2 analysts
    Revenue Consensus
    $73M
    Range$59M - $99M
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.71---
    Sep 26EST
    		-$-0.05---
    Jun 26
    Reported Aug 4
    		$-0.08$-0.09+11.11%Beat+20.0%
    Mar 26
    Reported May 7
    		$-0.08$-0.07-14.29%Miss+46.7%
    Dec 25
    Reported Feb 23
    		$-0.06$-0.11+45.75%Beat+25.0%
    Sep 25
    Reported Nov 4
    		$-0.07$-0.10+30.00%Beat+41.7%
    Jun 25
    Reported Aug 5
    		$-0.10$-0.10+0.00%Beat+50.0%
    Mar 25
    Reported May 12
    		$-0.15$-0.16+6.25%Beat+25.0%
    Dec 24
    Reported Mar 3
    		$-0.08$-0.13+38.46%Beat+78.9%
    Sep 24
    Reported Nov 12
    		$-0.12$-0.18+33.33%Beat+36.8%
    Jun 24
    Reported Aug 12
    		$-0.20$-0.15-33.33%Miss+37.5%
    Mar 24
    Reported May 9
    		$-0.20$-0.16-25.00%Miss+25.9%
    Dec 23
    Reported Mar 19
    		$-0.38$-0.18-111.11%Miss-40.7%
    Sep 23
    Reported Nov 8
    		$-0.19$-0.18-5.56%Miss+32.1%
    Jun 23
    Reported Aug 8
    		$-0.32$-0.23-39.13%Miss-33.3%
    Mar 23
    Reported May 11
    		$-0.27$-0.27+0.00%Beat-3.8%
    Dec 22
    Reported Mar 1
    		$-0.27$-0.22-22.73%Miss-17.4%
    Sep 22
    Reported Nov 9
    		$-0.28$-0.21-33.33%Miss-27.3%
    Jun 22
    Reported Aug 8
    		$-0.24$-0.24+0.00%Beat-4.3%
    Mar 22
    Reported May 10
    		$-0.26$-0.22-18.18%Miss-23.8%
    Dec 21
    Reported Mar 1
    		$-0.23$-0.21-9.52%Miss+23.3%
    Sep 21
    Reported Nov 12
    		$-0.22$-0.20-10.00%Miss-10.0%
    Jun 21
    Reported Aug 12
    		$-0.23$-0.12-91.67%Miss-15.0%
    Mar 21
    Reported May 14
    		$-0.21$-0.41+48.78%Beat-10.5%
    Dec 20
    Reported Mar 4
    		$-0.30$-0.18-66.67%Miss-87.5%
    Sep 20
    Reported Nov 9
    		$-0.20$-0.18-11.11%Miss-25.0%
    Jun 20
    Reported Aug 7
    		$-0.20$-0.19-5.26%Miss-17.6%
    Mar 20
    Reported May 11
    		$-0.19$-0.17-11.76%Miss+13.6%
    Dec 19
    Reported Mar 25
    		$-0.16$-0.20+20.00%Beat+27.3%
    Sep 19
    Reported Nov 5
    		$-0.16$-0.18+11.11%Beat+46.7%
    Jun 19
    Reported Aug 6
    		$-0.17$-0.24+29.17%Beat+51.4%
    Mar 19
    Reported May 8
    		$-0.22$-0.23+4.35%Beat+37.1%
    Dec 18
    Reported Mar 13
    		$-0.22$-0.31+29.03%Beat+29.0%
    Sep 18
    Reported Nov 7
    		$-0.30$-0.37+18.92%Beat+0.0%
    Jun 18
    Reported Aug 6
    		$-0.35$-0.38+7.89%Beat-20.7%
    Mar 18
    Reported May 7
    		$-0.35$-0.34-2.94%Miss-16.7%
    Dec 17
    Reported Mar 12
    		$-0.31$-0.33+6.06%Beat-6.9%
    Sep 17
    Reported Nov 7
    		$-0.30$-0.32+6.25%Beat+23.1%
    Jun 17
    Reported Aug 7
    		$-0.29$-0.31+6.45%Beat-
    Mar 17
    Reported May 8
    		$-0.30$-0.36+16.67%Beat-
    Dec 16
    Reported Mar 15
    		$-0.29$-0.43+32.56%Beat-
    Sep 16
    Reported Nov 10
    		$-0.39$-0.45+13.33%Beat-

    Key Metrics

    Valuation
    P/E Ratio-27.76EV/EBITDA-8.99x
    Price/FCF-29.30xFCF Yield-3.41%
    Profitability
    Profit Margin0.00%Operating Margin-120.40%
    ROE0.00%ROIC-576.27%
    Financial Health
    Debt/Equity-1.14xInterest Coverage-7.32x
    Current Ratio5.72xQuick Ratio5.70x
    Trading Statistics
    Beta0.13Avg Volume8.74M
    52-Week High$12.4352-Week Low$1.95

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$7.99
    SMA 20$7.71
    SMA 50$7.83
    SMA 200$6.45
    EMA 10$7.99
    EMA 20$7.84
    EMA 50$7.73
    EMA 200$6.60

    MACD

    Line: 0.15Signal: 0.08Hist: 0.07

    ADX

    ADX: 18.2+DI: 31.9-DI: 17.8

    Aroon & PSAR

    Aroon Up96.0
    Aroon Down8.0
    PSAR$7.53

    Bollinger Bands

    Upper Band$8.47
    Lower Band$6.95
    %B Position1962%(Upper)
    Band Width0.72

    RSI (14-Day)

    Neutral
    54.2

    Momentum Oscillators

    Stoch %K68.9
    Stoch %D76.3
    Williams %R-53.4
    ROC (10d)6.3%
    Momentum0.48
    CCI (20d)96.2
    MFI (14d)64.4

    Volatility Measures

    ATR (14d)$0.43(5.4%)
    StdDev (20d)0.38
    Hist Vol53.1%(High)

    Volume Flow

    VWAP$8.11
    OBV744.8M
    AD Line-234.8M
    CMF (20d)0.089

    Volume Metrics

    Avg Vol (20d)8.6M
    Vol Ratio0.9x
    VWMA (20d)$7.70

    Pivot Points

    R3$9.29
    R2$9.03
    R1$8.71
    Pivot Point$8.45
    S1$8.13
    S2$7.87
    S3$7.55

    Advanced Oscillators

    TSI9.21
    Ultimate Osc51.1
    KST33.53

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$51.24M$44.21M$64.71M$32.06M$26.43M$16.52M$8.60M$6.11M$0$40,000$139,000$82,000
    Cost of Revenue$298,000$238,000$69,000$354,000$136,000$58,000$4.14M$0$0$0$4.56M$0
    Gross Profit$50.94M$43.97M$64.64M$31.71M$26.29M$16.46M$8.60M$6.11M$0$40,000$139,000$82,000
    Operating Expenses$112.64M$113.76M$-82,502,000$175.03M$97.57M$80.89M$-109,787,000$172.72M$200.76M$95.24M$85.53M$80.22M
    R&D$60.82M$67.99M$-42,611,000$102.46M$55.24M$48.23M$-66,351,000$100.89M$102.26M$53.35M$51.53M$48.40M
    SG&A$51.82M$45.77M$-39,891,000$72.56M$42.34M$32.65M$-43,436,000$71.83M$98.50M$41.88M$33.11M$31.82M
    Operating Income$-61,697,000$-69,791,000$62.23M$-111,260,000$-71,285,000$-64,429,000$110.19M$-160,506,000$-198,666,000$-95,196,000$-85,389,000$-80,136,000
    Interest Income$3.15M$2.31M$-922,000$4.13M$1.15M$887,000$-2,502,000$3.60M$3.78M$3.10M$484,000$-1,220,000
    Interest Expense$31.24M$28.46M$-2,466,000$55.17M$28.88M$28.86M$-23,242,000$80.49M$59.59M$37.49M$32.13M$35.02M
    Income Before Tax$-230,390,000$-632,788,000$97.52M$-134,618,000$-92,305,000$-129,900,000$161.16M$-171,504,000$-269,168,000$-134,130,000$-233,454,000$-95,642,000
    Income Tax Expense$0$0$-404,000$-35,000$269,000$-234,000$0$0$0$0$-40,000$0
    Net Income$-230,390,000$-632,797,000$97.89M$-134,548,000$-92,574,000$-129,666,000$161.16M$-171,504,000$-269,168,000$-134,130,000$-233,414,000$-95,642,000
    EBITDA$-200,166,000$-603,784,000$68.99M$-78,273,000$-60,705,000$-98,145,000$131.09M$-84,532,000$-185,068,000$-90,129,000$-190,251,000$-43,378,000
    EBIT$-202,301,000$-606,638,000$66.83M$-81,246,000$-64,574,000$-101,922,000$121.97M$-94,606,000$-194,912,000$-99,742,000$-201,812,000$-59,401,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IBRX

    News

    Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against ImmunityBio, Inc. (IBRX) and Encourages Stockholders to Learn More About the Investigation

    Bronstein, Gewirtz & Grossman, LLC has launched an investigation into ImmunityBio, Inc. (IBRX) regarding potential corporate wrongdoing by the company and its officers/directors. The firm is encouraging investors who purchased ImmunityBio securities before January 19, 2026, and still hold them, to contact them to learn more and assist with the investigation. The firm operates on a contingency fee basis, meaning no upfront cost for investors.

    ACCESS Newswire•8/25/26•
    Bearish

    Does ImmunityBio’s (IBRX) Jim Yong Kim Hire Transform Its Global Access Strategy For Immunotherapies?

    ImmunityBio, Inc. has appointed former World Bank president Dr. Jim Yong Kim as Vice Chairman, focusing on global relationships to expand access to its immunotherapy platform. This strategic hire is expected to significantly bolster the company's international rollout capabilities for products like ANKTIVA, especially following its recent marketing authorization in the UAE. While Dr. Kim's expertise strengthens the company's global access strategy, the article notes that investors should still be aware of potential challenges in adoption and reimbursement in new regions.

    Simply Wall Street•8/25/26•
    Somewhat-Bullish

    IBRX Stock Extends 3-Day Slide — Founder Teases New Trial In ‘Unstoppable’ Cancer-Treatment Push

    ImmunityBio (IBRX) founder Patrick Soon-Shiong revealed plans for a new clinical trial combining Novartis’ Pluvicto with an IL-15-based treatment to enhance targeted radiation therapy for cancer. The announcement comes as IBRX stock experienced a third consecutive day of losses, despite being up 6% for the month. ImmunityBio's flagship drug, Anktiva, an IL-15 based immune activator, is expanding its market reach and boosting sales, although the company continues to report significant net losses.

    TradingView•8/25/26•
    Neutral

    Does ImmunityBio’s (IBRX) Jim Yong Kim Hire Transform Its Global Access Strategy For Immunotherapies?

    ImmunityBio recently appointed former World Bank president Dr. Jim Yong Kim as Vice Chairman to focus on global relationships and access to its immunotherapy platform. This strategic hire leverages Dr. Kim's expertise in global health and development to bolster ImmunityBio's international expansion, especially following the recent marketing authorization for ANKTIVA in the UAE, which expanded the company's footprint to 34 countries. While Dr. Kim's role strengthens international capabilities, the core investment narrative still hinges on ANKTIVA's growth and successful global regulatory approvals and reimbursement.

    Simply Wall Street•8/24/26•
    Somewhat-Bullish

    ImmunityBio, Inc. (NASDAQ:IBRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

    ImmunityBio, Inc. (NASDAQ:IBRX) has received a "Moderate Buy" consensus rating from analysts, with six out of seven brokerages recommending a buy. The average 12-month price target is $14.20, significantly higher than the current share price of $7.72. Despite quarterly earnings missing analyst expectations, the company's revenue exceeded estimates, and institutional investors have been increasing their holdings.

    MarketBeat•8/19/26•
    Neutral

    Frequently Asked Questions About IBRX

    Does IBRX pay dividends?
    Immunitybio Inc (IBRX) does not currently pay a regular dividend.
    What is IBRX's market cap?
    Immunitybio Inc (IBRX) has a market capitalization of $8.43B with a current stock price of $8.05.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In